Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) FCF Margin: 2017-2025

Historic FCF Margin for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to -373.08%.

  • Arcus Biosciences' FCF Margin fell 42516.00% to -373.08% in Q3 2025 from the same period last year, while for Sep 2025 it was -193.33%, marking a year-over-year decrease of 12907.00%. This contributed to the annual value of -68.22% for FY2024, which is 21383.00% up from last year.
  • Per Arcus Biosciences' latest filing, its FCF Margin stood at -373.08% for Q3 2025, which was down 348.81% from -83.12% recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' FCF Margin ranged from a high of 3,616.67% in Q1 2022 and a low of -846.30% during Q2 2021.
  • In the last 3 years, Arcus Biosciences' FCF Margin had a median value of -241.03% in 2024 and averaged -242.04%.
  • Per our database at Business Quant, Arcus Biosciences' FCF Margin surged by 435,609bps in 2022 and then plummeted by 402,467bps in 2023.
  • Over the past 5 years, Arcus Biosciences' FCF Margin (Quarterly) stood at -19.84% in 2021, then slumped by 18,604bps to -205.88% in 2022, then tumbled by 9,734bps to -303.23% in 2023, then tumbled by 8,524bps to -388.46% in 2024, then crashed by 42,516bps to -373.08% in 2025.
  • Its FCF Margin stands at -373.08% for Q3 2025, versus -83.12% for Q2 2025 and -475.00% for Q1 2025.